Direct-to-Consumer (DTC) Genetic Testing Market Analysis

Direct-to-Consumer (DTC) Genetic Testing Market Analysis

Predictive testing held more than 19% share of the DTC genetic testing market in 2022. The ongoing advancements and upgrades of platforms to enhance the efficiency of genome analysis procedures are expected to boost the adoption of predictive testing solutions. Increasing focus on reducing the healthcare burden of rare genetic disorders is fueling the need for presymptomatic testing to effectively assess and prevent future complications, thus curbing the rising mortality rates. Furthermore, the rapid integration of technologies such as machine learning, and artificial intelligence will boost the product development.
 

In terms of revenue, the direct-to-consumer genetic testing market share from the over-the-counter (OTC) segment is estimated to reach over USD 2 billion by the end of 2032. The growing preference for OTC products and the optimum availability of an extensive range of DTC consumer genetic testing kits will augment the industry outlook. OTC drugs and tests are more affordable, convenient, and relatively less complex. OTC DNA tests are attracting numerous consumers as they help inform individuals of risks associated with inherited conditions and predict potential disorders based on family history. Furthermore, the emergence of the COVID-19 pandemic strongly emphasized the need for at-home kits, propelling the industry expansion.
 

Direct-to-consumer genetic testing market from the single nucleotide polymorphism (SNP) chips technology segment is anticipated to exhibit over 12% CAGR between 2023-2032. SNP chips are witnessing a significant surge in demand with the incessant need for technologically advanced and more sophisticated DTC genetic tests through superior accuracy and efficiency. A high preference for SNP chips can be attributed to their ability to measure both dosage changes and DNA polymorphism along with different applications, such as SNP microarray analysis required in cancer research. The increasing need to minimize errors in DTC genetic tests is anticipated to stir the deployment of SNP technology, complimenting the industry growth.
 

Europe DTC genetic testing market size is poised to surpass USD 2.7 billion by 2032 owing to the surging number of patients suffering from rare chronic illnesses and the subsequently reduced quality of life. As a result, several EU bodies are implementing ambitious strategies to curb the mortality rate and improve care for patients with rare genetic conditions, offering lucrative business prospects for DTC genetic testing providers in the region. U.S. direct-to-consumer genetic testing industry is poised to grow at over 11% CAGR from 2023 to 2032, driven by the growing occurrence of genetic disorders across the globe.